Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.49 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 5/20 | 0.49 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487435 | 0.91 | CTSL (0.40) | CTSLCTSBCTSSCTSKCCR1 | |
| SCHEMBL4188373 | 0.90 | CTSS (0.39) | CTSLCTSBCTSSCTSK | |
| SCHEMBL4186154 | 0.89 | CTSS (0.42) | CTSLCTSBCTSSCTSK | |
| SCHEMBL4183292 | 0.89 | USP30 (0.39) | CTSLCTSBCTSSCTSKUSP30 | |
| SCHEMBL4177802 | 0.88 | CTSS (0.44) | CTSLCTSBCTSSCTSK | |
| SCHEMBL4188282 | 0.88 | CTSS (0.54) | CTSLCTSBCTSSCTSKUSP30 | |
| SCHEMBL4188234 | 0.87 | CTSL (0.44) | CTSLCTSBCTSSCTSKCCR1 | |
| SCHEMBL4188233 | 0.87 | CTSL (0.44) | CTSLCTSBCTSSCTSKCCR1 | |
| SCHEMBL4175983 | 0.86 | KDM4E (0.43) | — | |
| SCHEMBL4183416 | 0.86 | CTSK (0.48) | CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
| EP-1869026-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105475-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | CTSL 867/4885CTSB 2311/4885CTSS 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.